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Psychological and behavioural impact of returning
personal results from whole-genome sequencing: the
HealthSeq project
Saskia C Sanderson*,1,2,3, Michael D Linderman1,4, Sabrina A Suckiel1, Randi Zinberg1, Melissa Wasserstein5,
Andrew Kasarskis1,4, George A Diaz1 and Eric E Schadt1,4
Providing ostensibly healthy individuals with personal results from whole-genome sequencing could lead to improved health and
well-being via enhanced disease risk prediction, prevention, and diagnosis, but also poses practical and ethical challenges.
Understanding how individuals react psychologically and behaviourally will be key in assessing the potential utility of personal
whole-genome sequencing. We conducted an exploratory longitudinal cohort study in which quantitative surveys and in-depth
qualitative interviews were conducted before and after personal results were returned to individuals who underwent whole-
genome sequencing. The participants were offered a range of interpreted results, including Alzheimer’s disease, type 2 diabetes,
pharmacogenomics, rare disease-associated variants, and ancestry. They were also offered their raw data. Of the 35 participants
at baseline, 29 (82.9%) completed the 6-month follow-up. In the quantitative surveys, test-related distress was low, although it
was higher at 1-week than 6-month follow-up (Z=2.68, P=0.007). In the 6-month qualitative interviews, most participants felt
happy or relieved about their results. A few were concerned, particularly about rare disease-associated variants and Alzheimer’s
disease results. Two of the 29 participants had sought clinical follow-up as a direct or indirect consequence of rare disease-
associated variants results. Several had mentioned their results to their doctors. Some participants felt having their raw data
might be medically useful to them in the future. The majority reported positive reactions to having their genomes sequenced, but
there were notable exceptions to this. The impact and value of returning personal results from whole-genome sequencing when
implemented on a larger scale remains to be seen.
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INTRODUCTION
Whole-genome and exome sequencing are increasingly used in
clinical, research, and commercial contexts. Whole-genome sequen-
cing (sequencing of most of the euchromatin DNA in a genome) and
exome sequencing (sequencing of the protein-coding parts of the
genome) are used for diagnosing rare diseases,1,2 large-scale research
into rare and common diseases,3 and are available commercially direct
to consumers.4 These technologies are more comprehensive and detect
more types of DNA variation than targeted genetic tests and single-
nucleotide polymorphism (SNP) arrays. However, the huge volume of
data produced by whole-genome sequencing in particular raises many
practical and ethical challenges. These include issues around informed
consent, data analysis, interpretation of rare variants, and return of
results and raw data.5–7
The increasing availability of whole-genome sequencing inside and
outside the clinic has prompted debates about its value for ostensibly
healthy individuals.8–10 The value of DNA-based information can be
thought of as the ratio of beneﬁts to harms, and has traditionally been
conceptualized as ‘clinical utility’ (usefulness in the clinic and impact
on clinical end points).11 However, genomic information may also
have personal and social value, for example, as entertainment,
learning, or a way to relate to others.12,13 Understanding how
individuals react to personal results will be key in assessing how they
themselves perceive the potential utility or value of whole-genome
sequencing.
Although studies have begun exploring issues related to the value of
personal genomic sequencing for healthy individuals,14–17 these largely
focus on health-related results. SNP-based studies have similarly
focused primarily on health-related results,18–20 often for a single
disease or trait.21–23 Current evidence from SNP-based tests suggests
that DNA-based disease risk information has little emotional impact
on people,18 and does not motivate them to improve health
behaviours.24,25 However, SNP-based tests generally do not detect
rare variants that may have more important roles in health.
Given that whole-genome sequencing will become the standard in
detecting genomic variation in the future, the full scope of potential
reactions to the wide range of personal results that may arise from
whole-genome sequencing, including rare disease-associated variants,
should be explored. Protection motivation theory (PMT)26 may
provide a useful theoretical framework for the health-related compo-
nent of this exploration. PMT is a social cognition model that arose
out of fear-arousing communications research, and is widely used as a
framework for understanding health behaviours. According to PMT,
individuals are motivated to engage in health-protective behaviours
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(‘protection motivation’) when they perceive a threat to their health
(‘threat appraisal’) and when they feel able to reduce that threat
through their actions (‘coping appraisal’). SNP-based tests may not
elicit strong behavioural responses because individuals appraise the
health threat conveyed by the disease risk information to be low, and
so are not motivated to act on it. However, rare disease-associated
variants may elicit stronger emotional reactions and thus stronger
protection motivation and subsequent behavioural reactions.
We therefore explored how healthy individuals reacted to receiving
a range of personal whole-genome sequencing results in the HealthSeq
project, using the PMT to guide our conceptual framework relating to
the health-related results. HealthSeq is an exploratory longitudinal
study designed to explore motivations for whole-genome sequencing,
satisfaction, and the impact of personal whole-genome sequencing
results. In light of the public fascination with aspects of genetics such
as ancestry,27 non-health as well as health-related results were offered.
Raw sequence data was also offered, given current discussions around
patients’ access to their personal clinical/research data.28–30 As
previously reported, most (33/35) HealthSeq participants wanted all
the available results, and expressed a range of motivations, including
learning personal health-related information, obtaining ancestry
information, contributing to research, and satisfying curiosity.31 We
have also previously reported on participants’ satisfaction with the ﬁrst
genetic counselling session.32
The overarching aim of this study was to explore how people react
to receiving personal results from whole-genome sequencing. The
Speciﬁc Aims were to explore: (i) the emotional impact and perceived
value of personal results from whole-genome sequencing; (ii) the
behavioural impact; (iii) whether and how people’s reactions vary
by results categories (eg, ancestry vs type 2 diabetes risk); and
(iv) whether and how people’s reactions vary according to the personal
results they receive within those results categories (eg, increased vs
decreased risk of type 2 diabetes).
METHODS
This was a mixed-methods longitudinal cohort study in which participants
underwent whole-genome sequencing, received personal results, and completed
interviews at ﬁve time points (T1–T5). Recruitment and T1 procedures have
been previously described.31,32 After results were returned at T2 (see the section
‘Return-of-results appointments and reports’ below), telephone follow-up
interviews were conducted 1 week (T3), 6 months (T4), and 1 year (T5) later.
We used PMT to guide our conceptual framework (Supplementary Figure 1)
and inform our selection of constructs and measures relating to the health-
related results (Supplementary Table 1). For example, we assessed fear
(operationalized quantitatively as ‘test-related distress’), and intended and
actual behavioural reactions, in response to personal results from whole-
genome sequencing. We are not aware of any existing models that provide a
framework for both health-related and non-health-related personal results
simultaneously, so our formal framework focuses on responses to health-related
results only. However, the qualitative topic guide and analysis plan were
designed to also explore responses to the non-health-related results, as well as
other potentially important psychological constructs and behaviours (see the
section ‘Six-month follow-up interviews’ below). This paper describes the
return-of-results appointment, and presents ﬁndings from the T4 interviews
and repeated measures from T1 to T4.
Return-of-results appointments and reports
At the in-person return-of-results appointment (T2), the study genetic
counsellor and medical geneticist veriﬁed whether the participant still wanted
to receive the results categories they had consented to at T1. The personal
results were then returned. The participants were given a paper report
comprising the following categories of information and interpreted results:
sequencing quality; ancestry; physical traits (lactose intolerance, bitter taster
type, cilantro taster type, earwax dry/wet type); pharmacogenomics (simvasta-
tin, clopidogrel, warfarin); common polygenic disease risk (type 2 diabetes,
coronary artery disease, age-related macular degeneration (AMD)); Alzheimer’s
disease risk; monogenic disease carrier variants (‘rare carrier variants’); and
monogenic disease variants (‘rare disease-associated variants’). The genetic
counsellor and medical geneticist systematically reviewed the report with the
participant, reviewing each section, providing background and then discussing
the meaning of the results. Questions were answered and concerns were
addressed for each section before moving to the next. The participants were
given the option to receive their raw sequencing data on a portable hard drive.
Results sessions lasted approximately 1 h depending on the quantity of results
and participant concerns. Immediately after the counselling session, the
participants completed the T2 interview with the research coordinator. On
completion of the study (ie, after all follow-up interviews had been completed),
the results reports were reviewed and all rare variants that had been classiﬁed as
pathogenic or likely pathogenic were re-interpreted, to examine whether any
classiﬁcations had changed in the intervening time.
Six-month follow-up interviews
The T4 telephone interview schedule comprised two parts. Part one was a topic
guide containing seven broad questions plus suggested prompts. The questions
were developed by a multidisciplinary team and informed by PMT and other
relevant literature. The questions were designed to explore reactions to personal
results from whole-genome sequencing; understanding and recall of results; and
satisfaction with procedures and materials. This paper focuses on reactions to
personal results from whole-genome sequencing. The relevant questions in the
topic guide included: How are you feeling about your decision to get your
genome sequenced? How did your genome sequencing results make you feel?
Did your results inﬂuence your behaviour in any way? If yes, how? Have you
shared or intend to share your results with anyone? If yes, with whom and why?
Part two of the interview schedule contained valid, reliable measures of
depression,33 anxiety,34 quality of life (QoL),35 positive experiences;36 PMT-
related measures were fear (test-related distress36) and lifestyle behaviours.37
Interviews were audio-recorded and transcribed verbatim for qualitative
analysis. Responses to closed-ended questions were entered into a database
for quantitative analysis.
Analyses
A thematic framework approach was developed by SCS and SAS for the analysis
of the transcripts from part one of the interviews.38,39 The initial broad themes
were guided by the literature and the overarching objectives, and included two
sets of themes: emotional reactions, perceived value, and behavioural reactions;
and reactions to results categories and offer of raw data. For the latter set, sub-
themes were determined by the categories in the results reports, for example,
reactions to ancestry results, reactions to pharmacogenomics results, and so on.
For the former set, more differentiated sub-themes were generated in a
‘bottom-up’ manner based on an in-depth analysis of 10 interview transcripts:
SCS and SAS each analysed ﬁve transcripts, individually developed a set of
themes and sub-themes based on these analyses, compared the two sets,
resolved any differences through discussion, and jointly produced a single
codebook. For behavioural reactions, each sub-theme (eg, ‘Communication
with family’) was further sub-categorized into ‘Action’ (has already done this)
‘Intention’ (plans to do this), and ‘None’ (has not done this and does not plan
to). The codebook is available from the authors on request.
SCS used this codebook to code all T4 transcripts using software package
NVivo 10. Although not the primary focus here, SCS also read all T2 and T3
transcripts to establish that no key themes were being missed in the T4
transcripts. SAS coded a subset of T4 transcripts and assisted in resolving any
uncertainties in coding. A non-exclusive coding approach was used, for
example, a text segment could be coded as both ‘negative emotional reaction’
and ‘reactions to Alzheimer’s disease results’.
To address Speciﬁc Aims 1 and 2, the coded text passages were explored and
categorized by SCS and SAS into a ﬁnal characterization of participants’
emotional and behavioural reactions overall. To facilitate the analyses for
Speciﬁc Aims 3 and 4, a tabular thematic framework in Microsoft Excel was
used. In this framework, each participant interview corresponded to one row.
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The columns corresponded to results categories. Each results category (eg,
Alzheimer’s disease) was represented by two columns. The ﬁrst column
contained the participant’s actual result (eg, APOE e3/e4). The second column
contained their reaction to the result (eg, if a text segment from that
participant’s interview had been coded as ‘Reactions to Alzheimer’s disease
result’, then that coded text would be entered here). This thematic framework
approach allowed us to explore whether different themes emerged for different
categories of genomic results, as well as for different personal results within
those categories. It also allowed us to read across the rows, facilitating
understanding of individual participants’ stories.
For the measures in part two of the interview, variables were described using
means, standard deviations, and frequencies. Changes over time were assessed
using repeated-measures analysis of variance (ANOVA) and the Wilcoxon
signed-rank test. All statistical analyses were conducted using software package
SPSS v.20 (IBM, Chicago, IL, USA).
RESULTS
Socio-demographic characteristics
Twenty-nine (82.9%) of the 35 participants completed T4 and were
included in the analyses. As Table 1 shows, the participants were 41%
female, aged 26–68 years, 79% White non-Hispanic, and 52% had
annual household incomes over $150000.
Results returned to participants
Seven participants received results reports that included one or more
pathogenic (P) or likely pathogenic (LP) rare disease-associated variants
results. Participant 15 was informed he had an LP variant associated
with Brugada syndrome and was one of two participants who received
APOE e4/e4 results indicating increased Alzheimer’s disease risk. Two
participants received genetic risk scores (GRSs) indicating a likelihood
ratio of AMD greater than 2.0. Most (25/29) were informed they had at
least one variant classiﬁed as P/LP for carrier status. Table 2 summarizes
each participant’s results, and shows which P/LP disease-associated
variants results were re-classiﬁed, for example, as variants of uncertain
signiﬁcance (VUS), after the study had ended.
Emotional and behavioural reactions overall: themes and example
quotes
Positive emotional reactions. Most participants expressed positive
feelings about having had their genomes sequenced. Six major themes
emerged: (i) feeling happy or relieved; (ii) it was interesting;
(iii) feeling glad to have contributed to research; (iv) the results or
data might be useful to them in the future; (v) the results made them
feel more connected to the world; (vi) it was fun. Among the partici-
pants who felt happy, some felt this way because they were excited by
the science, for example, ‘I’m geeked. I’m still geeked. I was geeked at
the beginning. I’m geeked now. I love it. I think it’s one of the best
things I ever did.’ [#32, male, 35–39 years]. See Supplementary Table 2
for sub-themes and additional example quotes.
Negative emotional reactions. Although most participants reacted
positively, a few expressed negative reactions. Six major themes
emerged: (i) concern; (ii) disappointment; (iii) indifference;
(iv) confusion; (v) desire for more results; (vi) not relevant to them.
Among those who felt concerned, participants talked about the
implications for their health, insurance, and their results going into
their medical records if they sought medical follow-up. Among those
who felt disappointed, for some this was because they had hoped to
get information about a speciﬁc disease or trait. For others, the results
did not meet their expectations and their disappointment was with the
general scope of the results, for example, ‘I left the whole process
feeling disappointed a little bit in terms of what I actually learned…’
[#13, male, 50–54 years]. See Supplementary Table 3 for sub-themes
and example quotes.
Behavioural reactions. Many participants had acted on their results.
Four major themes emerged: (1) shared results with family and
friends; (2) sought further information from family or online;
(3) shared results with a healthcare provider; (4) made lifestyle
Table 1 Socio-demographic characteristics of participants
Characteristic
Participants who completed
6-month follow-up (N=29)
Gender
Male 17 (58.6%)
Female 12 (41.4%)
Age (years), mean (SD), range 48.6 (12.1), 26–68
Age groups
18–29 years 3 (10.3%)
30–39 years 5 (17.2%)
40–49 years 5 (17.2%)
50–59 years 9 (31.0%)
60+ years 7 (24.1%)
Race/Ethnicity
African American 1 (3.4%)
Asian 1 (3.4%)
Hispanic/Latino 2 (6.9%)
More than one race 2 (6.9%)
White non-Hispanic 23 (79.3%)
Education level
Less than Bachelor’s degree 0 (0.0%)
Bachelor’s degree 10 (34.5%)
Master’s degree 12 (41.4%)
PhD/MD/JD 7 (24.1%)
Employment status
Employed full-time 24 (82.8%)
Employed part-time 1 (86.2%)
Missing data 4 (13.8%)
Annual household income
Below $20000 2 (6.9%)
$20 000–$39 000 0 (0.0%)
$40 000–$59 000 4 (13.8%)
$60 000–$79 000 1 (3.4%)
$80 000–$150 000 6 (20.7%)
Over $150 000 15 (51.7%)
Chose not to answer 1 (3.4%)
Number of individuals in household (besides oneself)
Mean (SD), range 1.3 (1.5), 0–5
Number of biological children
Mean (SD), range 0.79 (0.98), 0–3
No children 16 (55.2%)
1 child 4 (13.8%)
2 children 8 (27.6%)
3 children 1 (3.4%)
Note that all the data are expressed as number (%), unless otherwise indicated.
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changes. Among those who had shared their results with a healthcare
provider, the majority had just mentioned them at a pre-scheduled
appointment. One had their results put in their medical record. One
had made an appointment and had a consultation, including tests and
procedures, with a healthcare provider as a direct consequence, and
one as an indirect consequence, of their results (see the ‘Rare disease-
associated variants’ section below). Many participants talked about
why they had not shared their results with a healthcare provider. Only
a few had made lifestyle changes because of their results. See
Supplementary Table 4 for sub-themes and example quotes.
Reactions to speciﬁc results: themes and example quotes
Rare disease-associated variants. Two of the seven participants who
received P/LP rare disease-associated variants results were concerned
about and acted on their results. In the ﬁrst case, participant 15 (who
received the LP Brugada-associated variant result) said, ‘It was pretty
concerning to me because it is a sudden cardiac death mutation, so it’s
one of those things that, it really can strike at any time, and it’s, so I
was scared for that reason.’ [#15, male, 25–29 years]. The result
directly prompted him to make an appointment and have a consulta-
tion, including tests and procedures, with a healthcare provider: ‘So I
was able to meet with [the cardiologist], and he did the EKG, which
didn’t ﬁnd anything pathological… After talking to him, I was
reassured…’. He anticipated that the result might be empowering in
the future: ‘It was stressful in the short-term… I think going forward
I’ll be concerned about the risk of sudden cardiac death, but I think
hopefully this information will be empowering.’ Over time, he had
become less concerned with the Brugada-associated variant, and more
concerned about his Alzheimer’s disease e4/e4 result, saying, ‘I think I
heard the APOE4 APOE4 high risk of Alzheimer’s, and kind of didn’t
think much about that at that point in time because my concern was
more on the immediate risk of death, but… I’ve probably thought
more and more about the Alzheimer’s than about Brugada.’ [#15,
male, 25–29 years]. In the second case, participant 7 was concerned
enough about her two rare cardiac disease-associated variant results to
seek further information from relatives about family cardiac health
history, which then prompted her to make an appointment and have a
consultation with a healthcare provider. See Table 3 for further details.
Alzheimer’s disease. Both the participants who received APOE e4/e4
results were concerned. One of the seven participants who received e3/
e4 results was confused and unclear about the health implications. See
Table 3 for further details.
Multifactorial diseases. The multifactorial (polygenic) type 2 diabetes
and coronary artery disease results generally had little impact on
participants. Of the two participants who had received GRSs above 2.0
for AMD, one had shared their result with their healthcare provider at
a pre-scheduled appointment, and the other intended to make an
appointment with an ophthalmologist but had not done so yet.
Rare carrier variants. The rare carrier variant results generally had
little impact, although a few participants said they might be useful to
them or their children for reproductive decision-making in the future.
Some felt these results were not relevant to them, and that they should
have opted out of this section.
Pharmacogenomics. The participants found the pharmacogenomics
results interesting. Some felt these results might be useful to them
clinically in the future. Some had a desire for more results in this
category, and would have liked to know about more medications in
general, and about antidepressants speciﬁcally.Ta
bl
e
2
(C
on
tin
ue
d
)
Ad
di
tio
na
ld
et
ai
ls
re
ga
rd
in
g
P/
LP
di
se
as
e
va
ria
nt
s
re
su
lts
re
tu
rn
ed
ID
G
en
de
r
Ag
e
Ch
ild
re
n
Su
m
m
ar
y
of
he
al
th
-r
el
at
ed
re
su
lts
an
d
ra
w
da
ta
re
tu
rn
ed
N
om
en
cl
at
ur
e
As
so
ci
at
ed
di
se
as
e
In
te
rp
re
ta
tio
n
38
M
al
e
45
–
4
9
ye
ar
s
1
1
P
di
se
as
e;
1
P
/L
P
ca
rr
ie
r;
e3
/e
4
;
T2
D
1
.0
3
;
C
A
D
0
.9
6
;
A
M
D
1
.0
2
;
ra
w
da
ta
Y
M
_0
0
2
0
1
6
.1
(F
LG
):
c.
2
2
8
2
_2
2
8
5
de
l-
C
A
G
T
(p
.S
7
6
1
C
fs
X3
6
)
Ic
ht
hy
os
is
vu
lg
ar
is
,
dr
y
sk
in
co
nd
i-
tio
n
(s
em
i-d
om
in
an
t)
P
at
ho
ge
ni
c
(P
)
3
9
M
al
e
5
5
–
5
9
ye
ar
s
3
0
P
/L
P
di
se
as
e;
5
P
/L
P
ca
rr
ie
r;
e3
/e
2
;T
2D
0
.6
9
;C
A
D
1
.0
7
;
A
M
D
0
.6
5
;
ra
w
da
ta
Y
—
—
—
40
M
al
e
65
–
6
9
ye
ar
s
0
1
P
di
se
as
e;
0
P
/L
P
ca
rr
ie
r;
e3
/e
3
;
T2
D
0
.5
8
;
C
A
D
1
.1
4
;
A
M
D
0
.1
5
;
ra
w
da
ta
Y
N
M
_1
9
8
5
7
8
.3
(L
R
R
K
2)
:c
.6
0
5
5
G
4
A
(p
.G
2
0
1
9
S
)
P
ar
ki
ns
on
’s
di
se
as
e,
la
te
-o
ns
et
(in
co
m
pl
et
e
pe
ne
tr
an
ce
)
P
at
ho
ge
ni
c
(P
)
Ab
br
ev
ia
tio
ns
:
AM
D
,
ag
e-
re
la
te
d
m
ac
ul
ar
de
ge
ne
ra
tio
n
ge
ne
tic
ris
k
sc
or
e;
CA
D
,
co
ro
na
ry
ar
te
ry
di
se
as
e
ge
ne
tic
ris
k
sc
or
e;
N
,
no
;
T2
D
,
ty
pe
2
di
ab
et
es
ge
ne
tic
ris
k
sc
or
e;
Y,
ye
s.
To
ta
l
n
=
29
.
B
ol
d
fo
nt
hi
gh
lig
ht
s
pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
P
/L
P
ra
re
di
se
as
e-
as
so
ci
at
d
va
ria
nt
s
re
su
lts
,
AP
O
E
e4
/e
4
re
su
lts
in
di
ca
tin
g
in
cr
ea
se
d
ris
k
of
Al
zh
ei
m
er
's
di
se
as
e,
an
d/
or
A
M
D
G
R
S-
ba
se
d
re
la
tiv
e
ris
k
sc
or
es
gr
ea
te
r
th
an
2
.0
.
Psychological and behavioural impact of genome sequencing
SC Sanderson et al
285
European Journal of Human Genetics
Ta
bl
e
3
S
um
m
ar
y
of
re
su
lts
re
tu
rn
ed
an
d
pa
rt
ic
ip
an
ts
’
re
ac
tio
ns
by
re
su
lts
ca
te
go
ry
:
qu
al
ita
tiv
e
ou
tc
om
es
Pe
rs
on
al
ge
no
m
ic
re
su
lts
ca
te
go
rie
s
Pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
ea
ch
re
su
lt
Su
m
m
ar
y
of
pa
rt
ic
ip
an
ts
’
re
sp
on
se
s
in
th
e
qu
al
ita
tiv
e
6-
m
on
th
fo
llo
w
-u
p
in
te
rv
ie
w
s
N
%
R
ar
e
di
se
as
e
va
ria
nt
s
P
at
ho
ge
ni
c
va
ria
nt
(s
)
Li
ke
ly
pa
th
og
en
ic
va
ria
nt
(s
)
P
at
ho
ge
ni
c
an
d
lik
el
y
pa
th
o-
ge
ni
c
va
ria
nt
(s
)
N
o
pa
th
og
en
ic
/li
ke
ly
pa
th
og
en
ic
va
ria
nt
s
3 4 0 2
3
1
0
.3
1
3
.8
0
.0
7
9
.3
Tw
o
of
th
e
7
pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
‘p
at
ho
ge
ni
c’
or
‘li
ke
ly
pa
th
og
en
ic
’
(P
/L
P)
ra
re
di
se
as
e
va
ria
nt
re
su
lts
w
er
e
co
nc
er
ne
d
ab
ou
ta
nd
ha
d
ac
te
d
on
th
ei
rr
es
ul
ts
.T
he
ﬁ
rs
t
(#
1
5
,
m
al
e,
2
5
–
2
9
ye
ar
s)
ha
d
m
ad
e
an
ap
po
in
tm
en
t
an
d
ha
d
a
co
ns
ul
ta
tio
n,
in
cl
ud
in
g
te
st
s
an
d
pr
oc
ed
ur
es
,
w
ith
a
he
al
th
ca
re
pr
ov
id
er
,
as
a
di
re
ct
co
ns
eq
ue
nc
e
of
hi
s
SC
N
5A
B
ru
ga
da
-a
ss
oc
ia
te
d
re
su
lt;
th
e
se
co
nd
(#
0
7
,
fe
m
al
e,
5
5
–
5
9
ye
ar
s)
ha
d
so
ug
ht
fu
rt
he
r
in
fo
rm
at
io
n
fr
om
fa
m
ily
ab
ou
t
he
r
N
EB
L
an
d
S
N
TA
1
re
su
lts
,
an
d
th
is
ha
d
th
en
pr
om
pt
ed
he
r
to
al
so
ha
ve
a
ca
rd
ia
c
co
ns
ul
ta
tio
n
w
ith
a
he
al
th
ca
re
pr
ov
id
er
.
B
ot
h
ha
d
co
nc
er
ns
ab
ou
t
th
e
im
pl
ic
at
io
ns
fo
r
he
al
th
an
d
in
su
ra
nc
e,
an
d
ha
d
so
ug
ht
fu
rt
he
r
in
fo
rm
at
io
n
on
lin
e.
Th
e
ot
he
r
5
pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
P
/L
P
di
se
as
e
va
ria
nt
re
su
lts
ha
d
lit
tle
em
ot
io
na
l
or
be
ha
vi
ou
ra
l
re
ac
tio
ns
to
th
es
e.
P
ar
tic
ip
an
ts
w
ho
di
d
no
t
ha
ve
an
y
ra
re
di
se
as
e
va
ria
nt
s
id
en
tiﬁ
ed
in
th
ei
r
re
su
lts
re
po
rt
s
ha
d
lit
tle
em
ot
io
na
l
or
be
ha
vi
ou
ra
l
re
ac
tio
n
to
th
es
e
re
su
lts
.
Al
zh
ei
m
er
’s
di
se
as
e
AP
O
E
e4
/e
4
AP
O
E
e3
/e
4
AP
O
E
e3
/e
3
AP
O
E
e3
/e
2
2 7 1
9 1
6
.9
2
4
.1
6
5
.5
3
.4
B
ot
h
pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
AP
O
E
e4
/e
4
re
su
lts
w
er
e
co
nc
er
ne
d.
O
ne
(#
1
5
,
m
al
e,
2
5
–
2
9
ye
ar
s)
ha
d
al
so
re
ce
iv
ed
th
e
SC
N
5A
B
ru
ga
da
-a
ss
oc
ia
te
d
di
se
as
e
va
ria
nt
:h
e
in
iti
al
ly
di
d
no
t
fo
cu
s
on
th
e
e4
/e
4
re
su
lt
as
he
w
as
m
or
e
co
nc
er
ne
d
ab
ou
t
th
e
SC
N
5A
va
ria
nt
;
ho
w
ev
er
,
ov
er
tim
e,
he
be
ca
m
e
le
ss
fo
cu
se
d
on
th
is
,a
nd
m
or
e
co
nc
er
ne
d
ab
ou
t
th
e
A
lz
he
im
er
’s
ris
k.
Th
e
ot
he
r
(#
3
2
,m
al
e,
3
5
–
3
9
ye
ar
s)
w
as
co
nc
er
ne
d,
al
th
ou
gh
he
w
as
ha
pp
y
ab
ou
t
th
e
ex
pe
rie
nc
e
in
ge
ne
ra
l,
an
d
ve
ry
ex
ci
te
d
by
th
e
sc
ie
nc
e.
N
ei
th
er
ha
d
di
sc
us
se
d
th
ei
r
re
su
lts
w
ith
a
do
ct
or
.
A
lth
ou
gh
th
er
e
w
as
lit
tle
im
pa
ct
of
th
e
e3
/e
4
re
su
lts
on
m
os
tp
ar
tic
ip
an
ts
,o
ne
w
as
co
nc
er
ne
d
(#
1
1
,m
al
e,
6
0
–
6
4
ye
ar
s)
:h
e
ha
d
so
ug
ht
fu
rt
he
ri
nf
or
m
at
io
n
on
lin
e,
bu
tt
hi
s
ha
d
no
tr
ed
uc
ed
hi
s
co
nf
us
io
n
an
d
he
re
m
ai
ne
d
co
nc
er
ne
d;
he
ha
d
no
td
is
cu
ss
ed
th
e
re
su
lt
w
ith
a
do
ct
or
,i
n
pa
rt
du
e
to
in
su
ra
nc
e
co
nc
er
ns
;h
e
ha
d
st
ar
te
d
to
us
e
a
br
ai
n-
tr
ai
ni
ng
ap
p.
S
om
e
pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
e3
/e
3
or
e2
/e
3
re
su
lts
ex
pr
es
se
d
re
lie
f;
m
an
y
di
d
no
t
re
ac
t
pa
rt
ic
ul
ar
ly
to
th
e
re
su
lt.
Ty
pe
2
di
ab
et
es
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+a
ge
1
8
.9
%
to
4
5
.2
%
Th
es
e
re
su
lts
ha
d
lit
tle
em
ot
io
na
l
or
be
ha
vi
ou
ra
l
im
pa
ct
on
m
os
t
pa
rt
ic
ip
an
ts
.
A
fe
w
pa
rt
ic
ip
an
ts
m
ad
e
lif
es
ty
le
ch
an
ge
s
in
re
sp
on
se
to
in
cr
ea
se
d
ris
k
re
su
lts
.
2
4
va
ria
nt
s
G
R
S
-b
as
ed
re
la
tiv
e
ris
k
0
.5
8
to
1
.7
7
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+a
ge
+G
R
S
1
1
.0
%
to
5
5
.5
%
Co
ro
na
ry
ar
te
ry
di
se
as
e
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+a
ge
2
5
.0
%
to
5
0
.0
%
Th
es
e
re
su
lts
ha
d
lit
tle
em
ot
io
na
l
or
be
ha
vi
ou
ra
l
im
pa
ct
on
m
os
t
pa
rt
ic
ip
an
ts
.
Ve
ry
fe
w
pa
rt
ic
ip
an
ts
m
ad
e
lif
es
ty
le
ch
an
ge
s
in
re
sp
on
se
to
in
cr
ea
se
d
ris
k
re
su
lts
.
2
9
va
ria
nt
s
G
R
S
-b
as
ed
re
la
tiv
e
ris
k
0
.6
7
to
1
.6
6
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+a
ge
+G
R
S
1
9
.2
%
to
6
2
.7
%
Ag
e-
re
la
te
d
m
ac
ul
ar
de
ge
ne
ra
tio
n
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+a
ge
8
.0
%
to
2
5
.0
%
M
os
t
pa
rt
ic
ip
an
ts
re
ce
iv
ed
R
R
s
o
2
.0
an
d
m
os
t
di
d
no
t
re
ac
t
em
ot
io
na
lly
or
be
ha
vi
ou
ra
lly
to
th
es
e
re
su
lts
.
Psychological and behavioural impact of genome sequencing
SC Sanderson et al
286
European Journal of Human Genetics
Ta
bl
e
3
(C
on
tin
ue
d
)
Pe
rs
on
al
ge
no
m
ic
re
su
lts
ca
te
go
rie
s
Pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
ea
ch
re
su
lt
Su
m
m
ar
y
of
pa
rt
ic
ip
an
ts
’
re
sp
on
se
s
in
th
e
qu
al
ita
tiv
e
6-
m
on
th
fo
llo
w
-u
p
in
te
rv
ie
w
s
N
%
5
va
ria
nt
s
G
R
S
-b
as
ed
re
la
tiv
e
ris
k
Li
fe
tim
e
ris
k
es
tim
at
e:
ge
nd
er
+
ag
e
+
G
R
S
0
.1
5
to
8
.9
8
1
.2
%
to
7
1
.9
%
Tw
o
pa
rt
ic
ip
an
ts
re
ce
iv
ed
R
R
s
4
2
.0
.O
ne
of
th
es
e
pa
rt
ic
ip
an
ts
(#
2
0
,m
al
e,
2
5
–
2
9
ye
ar
s)
ha
d
a
re
le
va
nt
fa
m
ily
hi
st
or
y,
an
d
ha
d
sh
ar
ed
th
ei
r
re
su
lt
w
ith
th
ei
r
do
ct
or
at
a
pr
e-
sc
he
du
le
d
ap
po
in
tm
en
t
(R
R
2
.8
3
);
th
e
ot
he
r
(#
2
6
,
m
al
e,
3
5
–
3
9
ye
ar
s)
pl
an
ne
d
to
sh
ar
e
th
e
re
su
lt
w
ith
an
op
ht
ha
lm
ol
og
is
t
bu
t
ha
d
no
t
do
ne
so
ye
t
(R
R
8
.9
8
).
R
ar
e
ca
rr
ie
r
va
ria
nt
s
P
at
ho
ge
ni
c
va
ria
nt
(s
)
Li
ke
ly
pa
th
og
en
ic
va
ria
nt
(s
)
P
at
ho
ge
ni
c
an
d
lik
el
y
pa
th
o-
ge
ni
c
va
ria
nt
(s
)
N
on
e
1
6 2 7 4
5
5
.2
6
.9
2
4
.1
1
3
.8
Th
er
e
w
as
lit
tle
im
pa
ct
of
P
/L
P
di
se
as
e
ca
rr
ie
r
re
su
lts
on
m
os
tp
ar
tic
ip
an
ts
w
ho
re
ce
iv
ed
th
es
e
re
su
lts
.A
fe
w
sa
id
th
at
th
e
in
fo
rm
at
io
n
m
ig
ht
be
us
ef
ul
fo
r
th
ei
r
ow
n,
or
fo
r
th
ei
r
ch
ild
re
n’
s,
re
pr
od
uc
tiv
e
de
ci
si
on
-m
ak
in
g
in
th
e
fu
tu
re
.S
om
e
fe
lt
it
w
as
to
o
m
uc
h
in
fo
rm
at
io
n
an
d
no
t
re
le
va
nt
to
th
em
,a
nd
th
at
th
ey
sh
ou
ld
pe
rh
ap
s
ha
ve
op
te
d
ou
t
of
th
is
se
ct
io
n.
P
ar
tic
ip
an
ts
w
ith
no
ra
re
di
se
as
e
ca
rr
ie
r
va
ria
nt
s
id
en
tiﬁ
ed
ha
d
lit
tle
em
ot
io
na
l
or
be
ha
vi
ou
ra
l
re
ac
tio
n
to
th
es
e
re
su
lts
.
Ph
ar
m
ac
og
en
om
ic
s
C
lo
pi
do
gr
el
(P
la
vi
x)
E
xt
en
si
ve
m
et
ab
ol
iz
er
1
1
3
7
.9
S
om
e
pa
rt
ic
ip
an
ts
fe
lt
th
at
th
is
in
fo
rm
at
io
n
w
as
in
te
re
st
in
g,
an
d
so
m
e
fe
lt
th
at
it
m
ig
ht
be
us
ef
ul
to
th
em
in
th
e
fu
tu
re
.
A
fe
w
w
ou
ld
ha
ve
lik
ed
in
fo
rm
at
io
n
ab
ou
t
m
or
e
m
ed
ic
at
io
ns
,
in
cl
ud
in
g
an
tid
ep
re
ss
an
ts
.
U
ltr
ar
ap
id
m
et
ab
ol
iz
er
9
3
1
.0
In
te
rm
ed
ia
te
m
et
ab
ol
iz
er
9
3
1
.0
S
im
va
st
at
in
(Z
oc
or
)
N
or
m
al
ac
tiv
ity
1
9
6
5
.5
In
te
rm
ed
ia
te
ac
tiv
ity
8
2
7
.6
Lo
w
ac
tiv
ity
1
3
.4
In
su
fﬁ
ci
en
t
in
fo
rm
at
io
n
1
3
.4
W
ar
fa
rin
(C
ou
m
ad
in
)
**
*
**
*
**
*
Ph
ys
ic
al
tr
ai
ts
B
itt
er
ta
st
in
g
ty
pe
B
itt
er
ta
st
er
N
ot
bi
tt
er
ta
st
er
In
su
fﬁ
ci
en
t
in
fo
rm
at
io
n
1
7 7 5
5
8
.6
2
4
.1
1
7
.2
M
os
t
pa
rt
ic
ip
an
ts
di
d
no
t
re
ac
t
to
th
es
e
re
su
lts
.
A
fe
w
sa
id
th
ey
w
er
e
in
te
re
st
in
g
or
fu
n.
C
ila
nt
ro
ta
st
in
g
ty
pe
Le
ss
so
ap
y
ta
st
e
1
5
5
1
.7
M
or
e
so
ap
y
ta
st
e
3
1
0
.3
Le
as
t
so
ap
y
ta
st
e
3
1
0
.3
In
su
fﬁ
ci
en
t
in
fo
rm
at
io
n
8
2
7
.6
E
ar
w
ax
ty
pe
W
et
ea
rw
ax
2
7
9
3
.1
D
ry
ea
rw
ax
2
6
.9
Psychological and behavioural impact of genome sequencing
SC Sanderson et al
287
European Journal of Human Genetics
Ta
bl
e
3
(C
on
tin
ue
d
)
Pe
rs
on
al
ge
no
m
ic
re
su
lts
ca
te
go
rie
s
Pa
rt
ic
ip
an
ts
w
ho
re
ce
iv
ed
ea
ch
re
su
lt
Su
m
m
ar
y
of
pa
rt
ic
ip
an
ts
’
re
sp
on
se
s
in
th
e
qu
al
ita
tiv
e
6-
m
on
th
fo
llo
w
-u
p
in
te
rv
ie
w
s
N
%
La
ct
os
e
in
to
le
ra
nc
e
N
ot
la
ct
os
e
in
to
le
ra
nt
1
2
4
1
.4
P
os
si
bl
y
la
ct
os
e
in
to
le
ra
nt
1
1
3
7
.9
In
su
fﬁ
ci
en
t
in
fo
rm
at
io
n
6
2
0
.7
An
ce
st
ry
(la
rg
es
t
pe
rc
en
ta
ge
)
A
sh
ke
na
zi
Je
w
s
U
ta
hn
W
hi
te
s
N
E
ur
op
ea
n
S
pa
ni
ar
ds
9 6 3 3
3
1
.0
2
0
.7
1
0
.3
1
0
.3
M
an
y
pa
rt
ic
ip
an
ts
fo
un
d
th
es
e
re
su
lts
in
te
re
st
in
g,
an
d
so
m
e
fo
un
d
th
em
fu
n.
M
an
y
sh
ar
ed
th
es
e
re
su
lts
w
ith
th
ei
r
fa
m
ily
an
d
fr
ie
nd
s.
A
fe
w
sa
id
th
ei
r
re
su
lts
m
ad
e
th
em
fe
el
m
or
e
co
nn
ec
te
d
to
th
e
w
or
ld
.
Fr
en
ch
2
6
.9
A
rm
en
ia
ns
1
3
.4
A
fr
ic
an
A
m
er
ic
an
1
3
.4
B
as
qu
e
1
3
.4
B
am
ou
n
1
3
.4
S
in
ga
po
re
C
hi
ne
se
1
3
.4
M
ay
a
1
3
.4
R
aw
se
qu
en
ce
da
ta
Ye
s
N
o
2
6 3
8
9
.7
1
0
.3
S
ev
er
al
pa
rt
ic
ip
an
ts
fe
lt
th
at
th
ei
r
ra
w
se
qu
en
ce
da
ta
m
ig
ht
be
us
ef
ul
to
th
em
cl
in
ic
al
ly
in
th
e
fu
tu
re
if
th
ey
go
t
si
ck
.
Psychological and behavioural impact of genome sequencing
SC Sanderson et al
288
European Journal of Human Genetics
Physical traits. Most participants did not react to the physical traits
results, although a few said they were fun.
Ancestry. Many participants found their ancestry results very inter-
esting, and some found them fun. Many said that they had shared
these results in particular with family and friends, for example, ‘I was
telling my parents about it, some of my friends. Mostly people were
interested about the ancestry part.’ [#26, male, 35–39 years]. Some said
their ancestry results made them feel more connected to the world, for
example, ‘…It was surprising, and fascinating, and just enriching of
my sense of myself and my place in the world.’ [#18, male, 60–64
years].
Raw sequence data. Several participants felt that, even though most
could not open their raw sequence data ﬁles, their raw data might be
useful to them clinically in the future, for example, ‘Or if God forbid I
get cancer, myself, then I would probably want to revisit that data.’
[#07, female, 55–59 years].
Quantitative outcomes
At T1, anxiety and depression were low, and most participants said
they were in excellent or good health on the QoL measure: no changes
over time were detected in anxiety (F= 0.19, P= 0.67), depression
(F= 0.75, P= 0.52), or QoL (Z= 1.90, P= 0.058; see Figure 1 and
Supplementary Table 5). MICRA positive experiences scale scores were
lower at 1-week than 6-month follow-up (lower scores indicated more
positive experiences): mean (SD) scores were 2.55 (3.16) vs
7.45 (6.83), respectively (Z= 3.28, P= 0.001). On individual MICRA
items at T3, most said they were sometimes or often happy (28/29)
and relieved (27/29) about their results; again, these numbers were
slightly lower at T4 (Figure 2). This likely reﬂects that the MICRA asks
participants how often they have felt this way in the past week.
MICRA test-related distress scale scores were low: where 0= low
distress and 30=high distress, mean (SD) scores were 1.69 (4.00) at
T3 and 0.48 (1.27) at T4. Although low at both time points, the scores
were lower at T4 than T3 (Z= 2.68, P= 0.007). The examination of
the scatter plots suggested most participants had low distress but that
participant 15 had high distress at T3, which subsided by T4
(Figure 3). As shown in Figure 2, most participants reported they
never regretted having their genomes sequenced (27/29 at T3; 28/29 at
T4), and never or rarely worried because of their results (22/29 at T3;
25/29 at T4), on individual MICRA items. No changes in lifestyle
behaviours were detected (Supplementary Table 5).
DISCUSSION
In this study, most participants had positive emotional reactions to
receiving personal results from whole-genome sequencing. Our
ﬁndings support the suggestion that personal whole-genome sequen-
cing may have value for individuals in ways that go beyond narrow
deﬁnitions of health-related clinical utility, and that are consistent with
broader notions of personal utility or value.11–13
As observed in previous research using direct-to-consumer and
other SNP-based genetic results,18,25 few participants changed lifestyle
behaviours as a consequence of their whole-genome sequencing
results. This is consistent with PMT, and supported by our qualitative
ﬁndings: the small increases in diabetes and heart disease risk
conveyed in our study were insufﬁcient to elicit health-related fear
or protection motivation among participants. This may also reﬂect
well-known difﬁculties in facilitating lifestyle changes: even complex
interventions explicitly designed to change lifestyles achieve modest at
best improvements in lifestyles and related outcomes,40 and HealthSeq
did not provide behaviour change interventions.
Although there was little impact of the complex disease risk results
on the participants’ emotions or lifestyles, several were worried about
and/or acted on other results they received, in particular the rare
disease variants results. Taken together, these observations are con-
sistent with PMT: individuals who do not feel threatened by their
personal results from whole-genome sequencing (or do not feel they
can do anything to reduce their risk) may be unlikely to engage in
lifestyle change or to pursue clinical follow-up, but individuals who do
feel threatened by their results and who believe they might be able to
reduce the health threat may engage in subsequent health-protective
behaviours.
Figure 1 Anxiety and depression: quantitative outcomes. (a) Anxiety; (b) Depression.
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It is notable that one participant’s focus shifted over several months
from his Brugada-associated rare variant result to his Alzheimer’s
disease APOE e4/e4 result, as he processed and dealt with each in turn.
This highlights how reactions and counselling needs may change over
time, and that counselling protocols may need to reﬂect this. Ensuring
sufﬁcient support is available to people after receiving results is clearly
important, but it is not clear yet what the appropriate level of support
is nor how to ensure people get the support they need.
A further notable and challenging issue arising in the two cases
where ‘likely pathogenic’ variants directly or indirectly prompted
clinical follow-up, is that these variants were later re-classiﬁed as
VUSs after study completion. As the knowledge base about rare
variants grows, variants are likely to be re-classiﬁed over time.41–43
Studies addressing whether and how often people’s sequence data can
or should be re-interpreted, and how new interpretations should be
returned, are needed.
Several participants were unsure about the signiﬁcance of their
results, and uncertain about whether and what follow-up to pursue.
This was despite the results being returned in person by a genetic
counsellor and medical geneticist, and despite these participants being
early adopters with higher levels of education than the general
population. The ﬁnding that even under these circumstances some
participants struggled to understand their results and their implica-
tions underscore that signiﬁcant efforts will be needed to aid
comprehension of results in the future as whole-genome sequencing
expands to the wider population.
Several participants had mentioned their results to their regular
healthcare providers. This is consistent with previous research
Figure 2 Reactions to personal genomic sequencing results: quantitative outcomes.
Figure 3 Test-related distress: quantitative outcomes.
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reporting that over a third of consumers shared their direct-to-
consumer genetic results with a physician.44 These ﬁndings further
support the need for an educated healthcare workforce that is
prepared to interact with patients about their personal genomic
information whether or not that information has been obtained
within the clinic.45,46
Recent debates have explored whether research participants have the
right to access their own raw data, and whether greater efforts should
be made to facilitate this.28,30,47 Most HealthSeq participants opted to
receive and responded positively to having their raw data. Participants’
reasons for wanting their raw data were primarily that they felt having
it might be of value to them and their physicians in the future. This
novel ﬁnding provides early evidence that research participants may
value having their raw genomic data because they anticipate it may
help in their future clinical care.
Strengths of this study include the qualitative methods and the
greater age range compared with previous work.48 Limitations include
that participants were self-selected and had high levels of education
and income, so the ﬁndings are not generalizable to the wider
population. This was a small study, although the sample size was
not unusual for qualitative research.49,50 The PMT did not provide a
framework for exploring non-health-related results, positive emotional
reactions or communication behaviours. A more complete theoretical
framework within which to examine the psychological and beha-
vioural effects of results arising from whole-genome sequencing is
needed. Development of such a framework may be a particularly
valuable focus for future applied psychological research in the genomic
sequencing ﬁeld.
Research participants are key stakeholders in debates about the
future directions and value of offering personal results and data from
whole-genome sequencing. The ﬁndings from this in-depth study with
ostensibly healthy individuals suggest the possibility that currently
neither the beneﬁts nor harms of personal genome sequencing are
signiﬁcant for most individuals, but that there may be important
exceptions to this that warrant further investigation. The impact of
returning personal results from whole-genome sequencing results
when implemented on a larger scale remains to be seen.
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